Ana Luisa de Jesus Lopes Ribeiro, Maria Rosalia Pasca, Laurent R. Chiarelli, Giulia Degiacomi, Nathalie Barilone, Marco Fondi, Vadim Makarov, Leonardo B. Marino, Riccardo Manganelli, Marco Bellinzoni, Giuseppe Zanoni, Stewart T. Cole, Francesca Boldrin, Renato Fani, Alessio Porta, Giorgia Mori, Alain R. Baulard, Ruben C. Hartkoorn, Giovanna Riccardi, Jaroslav Blaško, Luiz Pedro S. de Carvalho, Pedro M. Alzari, Zuzana Svetlíková, Ivana Centárová, Elena Kazakova, Sean Ekins, Alexander Lepioshkin, Katarína Mikušová, Marta Esposito, University of Pavia, Russian Academy of Sciences [Moscow] (RAS), Microbiologie structurale - Structural Microbiology (Microb. Struc. (UMR_3528 / U-Pasteur_5)), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Ecole Polytechnique Fédérale de Lausanne (EPFL), University of Padova, Partenaires IRSTEA, Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Collaborative Drug Discovery, The Francis Crick Institute [London], Universidade Estadual Paulista Júlio de Mesquita Filho = São Paulo State University (UNESP), Comenius University in Bratislava, Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP), The research leading to these results received funding mainly from the European Community's Seventh Framework Program (Grant 260872). Additional funding was from the Slovak Research and Development Agency (Contract No. DO7RP-0015-11), the Francis Crick Institute which receives core funding from Cancer Research UK, the UK Medical Research Council (MC_UP_A253_1111), and the Wellcome Trust. The CDD TB database was funded by the Bill and Melinda Gates Foundation (Grant no. 49852). L.B.M. receives partial support from the FAPESP (2011/21232-1), CNPq (140079/2013-0), and CAPES PDSE (99999.003125/2014-09) programs., European Project: 260872,EC:FP7:HEALTH,FP7-HEALTH-2010-single-stage,MM4TB(2011), Università degli Studi di Pavia = University of Pavia (UNIPV), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Università degli Studi di Padova = University of Padua (Unipd), and Università degli Studi di Firenze = University of Florence (UniFI)
Summary To combat the emergence of drug-resistant strains of Mycobacterium tuberculosis, new antitubercular agents and novel drug targets are needed. Phenotypic screening of a library of 594 hit compounds uncovered two leads that were active against M. tuberculosis in its replicating, non-replicating, and intracellular states: compounds 7947882 (5-methyl-N-(4-nitrophenyl)thiophene-2-carboxamide) and 7904688 (3-phenyl-N-[(4-piperidin-1-ylphenyl)carbamothioyl]propanamide). Mutants resistant to both compounds harbored mutations in ethA (rv3854c), the gene encoding the monooxygenase EthA, and/or in pyrG (rv1699) coding for the CTP synthetase, PyrG. Biochemical investigations demonstrated that EthA is responsible for the activation of the compounds, and by mass spectrometry we identified the active metabolite of 7947882, which directly inhibits PyrG activity. Metabolomic studies revealed that pharmacological inhibition of PyrG strongly perturbs DNA and RNA biosynthesis, and other metabolic processes requiring nucleotides. Finally, the crystal structure of PyrG was solved, paving the way for rational drug design with this newly validated drug target., Graphical Abstract, Highlights • Two compounds activated by EthA kill M. tuberculosis through PyrG inhibition • EthA metabolite is active against PyrG and M. tuberculosis growth • Definition of the mechanism of activation and validation of PyrG as a new drug target, CTP synthetase PyrG, essential in Mycobacterium tuberculosis, could represent a new potential drug target. With a multidisciplinary approach, Mori et al. identify two compounds killing growing and dormant mycobacteria through PyrG inhibition, and define their mechanism of action.